Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wayne McNee

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
The New Zealand Medical Journal|November 15, 2003
More on DTCA and the cost of asthma inhalersWayne McNee
The New Zealand Medical Journal|May 27, 2003
Death of pharmacy or safer dispensing?Wayne McNee
The New Zealand Medical Journal|June 28, 2005
PHARMAC responds to the RMI's editorialPeter Moodie, Wayne McNee
The New Zealand Medical Journal|October 29, 2003
Direct-to-consumer advertising--yes it can compromise patient healthScott Metcalfe, Wayne McNee, Peter Moodie
Healthcarepapers|June 18, 2003
Our advice? Get a budget!Matthew Brougham, Scott Metcalfe, Wayne McNee
The New Zealand Medical Journal|July 20, 2005
PHARMAC welcomes debatePeter Moodie, Wayne McNee, Scott Metcalfe
The New Zealand Medical Journal|March 27, 2003
Response from PHARMAC: difficult choicesPeter Moodie, Scott Metcalfe, Wayne McNee
The New Zealand Medical Journal|June 28, 2005
PHARMAC and tobacco control in New Zealand: two licensed funded options are already availableScott Metcalfe, Peter Moodie, Wayne McNee
BMJ (Clinical Research Ed.)|February 11, 2003
Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis. Celecoxib's relative gastrointestinal safety is overstatedScott Metcalfe, Sean Dougherty, Wayne McNee
The New Zealand Medical Journal|September 1, 2005
PHARMAC responds to Stewart Mann on dihydropyridine calcium channel antagonistsAndrew Davies, Scott Metcalfe, Peter Moodie, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
The New Zealand Medical Journal|November 15, 2003
More on DTCA and the cost of asthma inhalersWayne McNee
The New Zealand Medical Journal|May 27, 2003
Death of pharmacy or safer dispensing?Wayne McNee
The New Zealand Medical Journal|June 28, 2005
PHARMAC responds to the RMI's editorialPeter Moodie, Wayne McNee
The New Zealand Medical Journal|October 29, 2003
Direct-to-consumer advertising--yes it can compromise patient healthScott Metcalfe, Wayne McNee, Peter Moodie
Healthcarepapers|June 18, 2003
Our advice? Get a budget!Matthew Brougham, Scott Metcalfe, Wayne McNee
The New Zealand Medical Journal|July 20, 2005
PHARMAC welcomes debatePeter Moodie, Wayne McNee, Scott Metcalfe
The New Zealand Medical Journal|March 27, 2003
Response from PHARMAC: difficult choicesPeter Moodie, Scott Metcalfe, Wayne McNee
The New Zealand Medical Journal|June 28, 2005
PHARMAC and tobacco control in New Zealand: two licensed funded options are already availableScott Metcalfe, Peter Moodie, Wayne McNee
BMJ (Clinical Research Ed.)|February 11, 2003
Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis. Celecoxib's relative gastrointestinal safety is overstatedScott Metcalfe, Sean Dougherty, Wayne McNee
The New Zealand Medical Journal|September 1, 2005
PHARMAC responds to Stewart Mann on dihydropyridine calcium channel antagonistsAndrew Davies, Scott Metcalfe, Peter Moodie, et al.
Pageof 2